Product image of Mivacurium Kalceks (Mivacurium) supplied by GNH India

Mivacurium Kalceks

Active Ingredient:
Mivacurium
Origin:
EU

Mivacurium Kalceks (Mivacurium)

Mivacurium, the active ingredient in Mivacurium Kalceks, is a neuromuscular blocking agent presented as an injectable solution for intravenous use. It provides short‑acting skeletal muscle relaxation to facilitate endotracheal intubation and to support muscle relaxation during surgical procedures in adult patients under anesthesia.

GNH India supplies Mivacurium Kalceks as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide. The company follows stringent quality standards and offers reliable global logistics to ensure timely delivery for clinical and surgical use. GNH India’s dedicated regulatory team assists with import documentation and compliance across regions.

Manufacturer / TM Owner

Kalceks

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Mivacurium is a short‑acting neuromuscular blocking agent used in anesthesia to produce rapid skeletal muscle relaxation.

  • Facilitation of endotracheal intubation: provides rapid, short‑duration muscle relaxation to allow safe airway placement.
  • Muscle relaxation during surgery: enables controlled relaxation of skeletal muscles throughout operative procedures.
  • Diagnostic procedures requiring brief neuromuscular blockade: allows temporary paralysis for specific investigations such as bronchoscopy.

How It Works

  • Mivacurium acts as a competitive antagonist at nicotinic acetylcholine receptors on the motor end‑plate of the neuromuscular junction. By occupying these receptors, it blocks acetylcholine‑induced depolarization, preventing nerve impulse transmission to skeletal muscle fibers and producing a rapid, reversible loss of muscle tone without central nervous system effects.

Side Effects

Mivacurium may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects

  • Transient flushing or erythema
  • Mild hypotension
  • Tachycardia
  • Bronchospasm
  • Nausea or vomiting
  • Headache

Serious or Rare Side Effects

  • Anaphylactic reaction
  • Prolonged apnea or respiratory depression
  • Malignant hyperthermia
  • Severe hypotension or cardiovascular collapse
  • Cardiac arrest

Precautions & Warnings

When using Mivacurium, clinicians should observe several precautionary measures to ensure patient safety.

  • Assess neuromuscular function: perform baseline monitoring before administration.
  • Monitor respiratory status: observe for apnea and ensure ventilatory support is available.
  • Avoid in patients with known hypersensitivity: discontinue immediately if allergic reaction occurs.
  • Use with caution in hepatic or renal impairment: altered metabolism may prolong effects.
  • Adjust dosing in the elderly or frail patients: consider reduced dose to prevent prolonged blockade.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Mivacurium can interact with other agents that influence neuromuscular transmission or cardiovascular stability.

Major Interactions (Avoid)

  • Aminoglycoside antibiotics (e.g., gentamicin): potentiate neuromuscular blockade.
  • Magnesium sulfate: enhances block and may cause prolonged paralysis.
  • Other neuromuscular blocking agents: additive effects increase risk of respiratory failure.
  • Lithium therapy: may increase sensitivity to blockade.

Moderate Interactions (Monitor Closely)

  • Volatile anesthetic gases (e.g., sevoflurane): can augment the depth of block.
  • Calcium channel blockers (e.g., verapamil): may slightly increase blockade duration.
  • Beta‑adrenergic blockers (e.g., propranolol): may affect cardiovascular response during administration.

Frequently Asked Questions

Mivacurium Kalceks is used by anesthesiologists to produce rapid, short‑lasting skeletal muscle relaxation. It facilitates endotracheal intubation and provides controlled muscle relaxation during surgical procedures, allowing surgeons to operate in a relaxed muscular environment.

Mivacurium works by competitively blocking nicotinic acetylcholine receptors at the neuromuscular junction. This prevents acetylcholine from triggering muscle fiber depolarization, thereby interrupting nerve‑muscle transmission and producing a reversible loss of muscle tone.

The specific dose of Mivacurium is determined by the prescribing clinician based on the patient’s weight, age, health status, and the intended procedure. Dosing is individualized and administered under continuous monitoring in a controlled clinical setting.

Safety data for Mivacurium in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and only under specialist supervision.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

Mivacurium is a short‑acting, non‑depolarizing blocker, offering a rapid onset and brief duration compared with longer‑acting agents such as rocuronium or vecuronium. This makes it useful for procedures where quick recovery of muscle function is desired.

Mivacurium should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. Keep the product in its original packaging until use and follow any additional handling instructions provided by the manufacturer.

Mivacurium is administered intravenously, typically as a single bolus injection that may be diluted in compatible IV fluids. Administration is performed by qualified healthcare professionals who monitor neuromuscular function and respiratory status throughout the procedure.

The most serious risks include anaphylactic reactions, prolonged apnea or respiratory depression, malignant hyperthermia, severe hypotension, and rare cases of cardiac arrest. Immediate recognition and supportive measures are essential to manage these events.

Mivacurium should be avoided in patients with known hypersensitivity to the drug, those with certain neuromuscular disorders (e.g., myasthenia gravis), and individuals with severe hepatic or renal impairment where drug clearance may be compromised.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Mivacurium

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT